

1 Please, cite this article as follows: García-Galán, M.J., Sordet, M., Buleté,  
2 A., Garric, J., Vulliet, E. (2017). “Evaluation of the influence of surfactants  
3 in the bioaccumulation kinetics of sulfamethoxazole and oxazepam in  
4 benthic invertebrates”. Science of the Total Environment 592, 554-564.

5

6 **Evaluation of the influence of surfactants in the bioaccumulation kinetics of**  
7 **sulfamethoxazole and oxazepam in benthic invertebrates**

8 **Maria Jesus Garcia-Galan<sup>1,2</sup>, Martin Sordet<sup>1</sup>, Audrey Buleté<sup>1</sup>, Jeanne Garric<sup>3</sup>, Emmanuelle**  
9 **Vulliet<sup>1</sup>**

10 <sup>1</sup> Université de Lyon, Institut des Sciences Analytiques, UMR 5280, Université Lyon1, ENS-Lyon. 5 Rue de la Doua,  
11 69100 Villeurbanne, France

12 <sup>2</sup> GEMMA, Environmental Engineering and Microbiology Research Group, Department of Hydraulic, Maritime and  
13 Environmental Engineering. Universitat Politècnica de Catalunya, c/ Jordi Girona 1-3, building D1, E-08034  
14 Barcelona, Spain

15 <sup>3</sup> IRSTEA, UR MAEP, Laboratoire d'écotoxicologie, 5 Rue de la Doua, 69100 Villeurbanne, France

16

17 **Keywords**

18 Pharmaceuticals, antibiotic, sentinel species, river ecosystem, uptake, bioconcentration

19

20

21

22

23

24

25

26

27

28 **Abstract**

29           The potential ecotoxicological effects of mixtures of contaminants in the aquatic  
30 environment are generating a global concern. Benthic invertebrates, such as the crustacean  
31 *Gammarus fossarum*, are key in the functioning of aquatic ecosystems, and are frequently  
32 used as sentinel species of water quality status. The aim of this work was to study the effects  
33 of a mixture of the most frequently detected surfactants in the bioconcentration kinetics of  
34 two pharmaceuticals in *G. fossarum*, evaluating their potential enhancing or suppressing  
35 effects. Laboratory exposure experiments for both pharmaceuticals and surfactants  
36 (concentration ratio 1:25) were set up for two individual compounds, the anxiolytic  
37 oxazepam and the antibiotic sulfamethoxazole. Gammarid samples were processed using  
38 microQuEChERS (Quick, Easy, Cheap, Effective, Rugged, and Safe) extraction.  
39 Pharmaceuticals concentration in the organisms was followed-up by means of nanoliquid  
40 chromatography coupled to tandem mass spectrometry (nanoLC-MS/MS). Results indicated  
41 a similar mode of action of the surfactants in the bioconcentration kinetics of both drugs,  
42 decreasing the accumulation rate in the organism.. Oxazepam showed a higher  
43 accumulation potential than sulfamethoxazole in all cases. Depuration experiments for  
44 oxazepam also demonstrated the high depurative capacity of gammarids, eliminating >50%  
45 of the concentration of oxazepam in less than 6 h.

## 46           **1. INTRODUCTION**

47           The environmental presence of pharmaceuticals (PhACs) has been studied in detail in the  
48 last two decades, providing enough data to evidence their ubiquity in both terrestrial and  
49 aquatic ecosystems [1-4]. PhACs are very bioactive molecules, designed to remain active for  
50 long periods of time, even after being metabolized in the organism. In order to keep that  
51 activity, they are generally highly resilient to biodegradation and so their removal during  
52 conventional wastewater treatment is usually incomplete. These results in their regular  
53 entrance onto the aquatic environment via discharge of wastewater effluents, constituting  
54 an ecotoxicological threat to different non-target aquatic organisms that can be exposed  
55 directly or indirectly to these substances [5-8]: directly by the discharge of these pollutants  
56 in wastewater treatment plants (WWTPs) and indirectly by the accumulation and  
57 biomagnification of these PhACs in the foodweb [9]. However, most of the studies have  
58 focused so far in bioaccumulation and toxicity of single PhACs in superior aquatic taxa such  
59 as fish ([10-16]), neglecting the potential effects in inferior taxonomic groups such as benthic  
60 macro and microinvertebrates. In a recent work by Huerta et al., [17], the antiinflammatories  
61 diclofenac and ibuprofen were found in larvae of caddisflies (*Hydropsipche* sp.) at  
62 concentrations of 183 ng g<sup>-1</sup> and 12.4 ng g<sup>-1</sup> (dry weight), respectively In a different study

63 by Grabicova et al. [18], six different PhACs were found also in *Hydrosipche* sp. in rivers from  
64 the Czech Republic, reaching concentrations of 85 ng g<sup>-1</sup> (wet weight, w.w.) in the case of  
65 the antibiotic azithromycin. Bioaccumulation in *Erpobdella* sp. (larvae of leeches) was also  
66 investigated in this study, and four different PhACs were detected, being diclofenac the  
67 compound found at the highest concentrations, ranging between 12-33 ng g<sup>-1</sup> w.w. Recently,  
68 Lagesson et al. [19] reached the conclusion that bottom-living organisms were the main  
69 receivers of PhACs, as they showed the highest PhACs concentrations in their tissues.  
70 Despite the little data available on their bioaccumulation capacity, most of the species  
71 aforementioned are frequently used as sentinel species, as they play a key role in the food  
72 chain and any alteration or loss of some of them could alter or degrade critical ecosystem  
73 processes. For instance, leaf litter detritivores species are responsible for shredding coarse  
74 particulate organic matter (CPOM) and releasing high amounts of nutrients in solution for  
75 other aquatic species such as bacteria, fungi or algae. The freshwater crustacean *Gammarus*  
76 sp. is one of the most frequently used species in ecotoxicology. They are widespread in  
77 European freshwater ecosystems, their physiology is well known and they are easy to  
78 culture in the laboratory. Furthermore, their role in the food web is key, as they are very  
79 efficient as detritivores, being able to process up to the 73% of riparian dead leaf inputs in  
80 the water course[20]. Gammarids also constitute themselves a major food source for other  
81 aquatic and terrestrial vertebrates such as fishes, turtles or birds. Despite their high capacity  
82 to accumulate pollutants ([21-23]), they are very sensitive to them and any physiological  
83 changes in the gammarid population may have effects at higher levels of the food chain [24,  
84 25].

85 In the last years, however, scientific concern has shifted from the conventional  
86 monitoring studies on the presence of these PhACs and other pollutants in different  
87 environmental compartments towards a broader vision of the problem, considering on one  
88 hand the presence not only of the parent drugs but also of metabolites and transformation  
89 products and their derived potential ecotoxicological effects [2, 26-33] and on the other the  
90 combined effects of the presence of mixtures of different PhACs (with or without other  
91 organic pollutants) and the potential synergetic, antagonistic or cumulative effects derived  
92 [13, 34-38]. Scientific efforts devoted to study mixture toxicity in aquatic environments have  
93 increased noticeably in the last years and had led to the creation and modification of new  
94 chemicals safety regulations, such as the existing European Union regulation REACH  
95 (Registration, Evaluation and Authorization of Chemicals) [39].

96           Taking all this into consideration it is very likely that PhACs coexist in the aquatic  
97 environment with other frequently detected pollutants such as perfluorinated compounds  
98 (PFOs), pesticides, flame-retardants or surfactants. The latter are one of the chemicals most  
99 produced and consumed worldwide [40, 41]. Contrary to PhACs, surfactants can be  
100 eliminated during wastewater treatment up to a 90-95% under optimized conditions, and  
101 they usually have low half-life times [42, 43]. However, their input in the receiving waters is  
102 regular, similarly to what happens to PhACs. Aquatic ecosystems are consequently facing a  
103 chronic exposure to both classes of contaminants, despite at low concentrations.

104           Surfactants show both hydrophilic and hydrophobic properties in their molecular  
105 structure, which gives them the ability to form micelles in solution (once they have reached  
106 a given concentration, the critical micelle concentration, (CMC)). These micellar structures  
107 confer them strong detergency and solubilisation properties that may have effects in other  
108 surrounding molecules. For instance, in soil ecosystems, hydrophobic organic compounds  
109 (HOCs) such as polycyclic aromatic hydrocarbons (PAHs) or perchloroethylene (PCE) can be  
110 solubilized by micelles (hydrocarbon core) and be transferred from soil to the aqueous  
111 pseudo-phase, leading to their desorption from soils. In fact, this remediation of  
112 contaminated soils and aquifer enhanced by surfactants application has become an effective  
113 and common treatment strategy [44]. Other works have also addressed their influence in  
114 the solubility of other hydrophobic compounds such as trichlorobenzene or  
115 dichlorodiphenyltrichloroethane (DDT) [45]. Surfactants, especially non-ionic species, are  
116 also widely used in pesticide formulations to increase their effectiveness in penetrating  
117 through cuticle structures of weeds, crops, and insects in crop fields [46]. In water  
118 ecosystems, it is well known that surfactants increase the water solubility of chemicals,  
119 depending equally on the physico-chemical properties and the nature of both substances.  
120 Recently, Chen et al. proved that the cationic surfactant cetyltrimethylammonium bromide  
121 (CTAB) significantly enhanced the photodegradation rate of triclosan in water, whereas  
122 anionic and neutral surfactants (sodium dodecyl benzene sulfonate, sodium dodecyl sulfate  
123 (SDS) and neutral polyoxyethylene (20) sorbitan monooleate, inhibited it [47]. The same  
124 CTAB, together with other surfactants (Triton X-100 and 4-dodecylbenzene sulfonic acid  
125 (SDBS)) seemed to reduce considerably the toxicity of different nanoparticles against the  
126 freshwater crustacean *Daphnia magna*, presumably due to the formation of aggregates of  
127 these nanoparticles [48]. On the contrary, other studies confirmed that, in presence of  
128 surfactants, the toxicity of these nanoparticles increased against certain plant species [49].  
129 Ecotoxicity of surfactants themselves is usually low. Generally, cationic surfactants are more

130 toxic against aquatic species (fish, water flea and algae) than anionic surfactants [40]. EC<sub>50</sub>  
131 values for cationic surfactants range from 0.1 to 10 ppm, whereas those for anionic  
132 formulations are 1 to 50 ppm [46].

133 All in all, it is obvious that aquatic ecosystems are submitted to a constant  
134 anthropogenic stress, as a wide variety of organic pollutants of very different nature enter  
135 surface waters on a daily basis, overcoming the equilibrium of these ecosystems and their  
136 capacity to neutralize their effects (dilution, in-stream attenuation, biodegradation etc).  
137 Reliable biomonitoring tools are therefore required to follow up the quality status of these  
138 ecosystems.

139 The aim of this study is to evaluate the influence of the background presence of a  
140 mixture of the most commonly detected surfactants on the bioaccumulation of selected  
141 PhACs in *Gammarus fossarum* in laboratory experiments. A novel method based on  
142 miniaturized QuEChERS, followed by nanoLC-MS/MS was applied to quantify the  
143 bioaccumulation of both PhACs individually in *G. fossarum*, allowing discerning  
144 bioconcentration kinetics under different conditions. The antibiotic sulfamethoxazole (SMX)  
145 and the benzodiazepine oxazepam (OXA) were chosen as target compounds, as they are  
146 frequently detected in environmental waters.

147

## 148 **2. MATERIALS AND METHODS**

### 149 **2.1. Chemicals and reagents**

150 Ultra-pure water (18.2 MΩcm) was obtained from a milliQ water system from  
151 Millipore (Saint-Quentin-en-Yvelines, France). HPLC-grade solvents methanol, acetonitrile,  
152 hexane, formic acid and ammonium acetate were obtained from Sigma-Aldrich (Saint-  
153 Quentin-Fallavier, France). Analytical standards for sulfamethoxazole (SMX) and oxazepam  
154 (OXA) (purity > 99%) were also purchased from Sigma-Aldrich. Stock standard solutions for  
155 each of the PhACs were prepared individually in MeOH at 1mg mL<sup>-1</sup> and stored in the dark at  
156 -20 °C. Solutions at the corresponding working concentrations were prepared accordingly.  
157 The commercial surfactants benzyldodecyldimethylammonium chloride (BDDAC),  
158 benzyldimethyltetradecyl ammonium chloride (BDTAC), cetyl betain, lauryl pyridinium,  
159 sodium 2-ethylhexyl sulfate, Triton X-100 and sodium dodecyl sulfate (SDS) were supplied by  
160 Sigma-Aldrich; Stepanquat GA 90 was supplied by Stepan Company (Chassieu, France);  
161 Texapon N 701 S and benzotriazole by BASF (Lyon, France); Incromine SD by Crodarom SAS

162 (Chanac, France), Comperlan 100 by Cognis (Boussens, France) and the LAS C10-13 mixture  
163 by Marseille soap company (Marseille, France). Stock solutions of the surfactants (200 mg/l)  
164 were prepared in pure water/LC grade methanol (50/50; v/v) and stored at 4°C in the dark. A  
165 mixture containing all the surfactants was prepared at 5 mg L<sup>-1</sup> using the appropriate  
166 dilution factor.

167 Custom QuEChERS salts (500 mg) were obtained from Agilent Technologies (Massy, France),  
168 and contained MgSO<sub>4</sub> (61.5 %), NaCl (15.4%), sodium citrate (15.4%) and disodium citrate  
169 sesquihydrate (7.7%). The pH of the salts was 5-5.5 and its purity was > 99.3%.

170

## 171 **2.2. Wastewater sampling**

172 Effluent wastewater was analyzed to fathom out the amounts of surfactants  
173 discharged into the aquatic environment. Composite samples were taken during 4  
174 consecutive days in November 2015 in the wastewater treatment plant (WWTP) of La  
175 Feysine (Lyon), which receives an average inflow of 66000 m<sup>3</sup> day<sup>-1</sup> of sewage from the  
176 Lyon peripheral area (capacity of 300,000 equivalent inhabitants). The collected water is first  
177 introduced into one of three Sedipac® 3D (lamellar settling tanks) to remove grease and grit,  
178 then the pre-treated water is forwarded to three biological treatment lines to remove  
179 carbonated pollution via oxygenation and nitrogen pollution via nitrification/denitrification.  
180 Samples were immediately filtered through a 0.7 µm pore size and directly pretreated for  
181 analysis.

182

## 183 **2.3. Test organisms**

184 Gammarids were collected at the beginning of November 2015 in a small affluent of  
185 the Bourbre river located in a pristine site located near the municipality of Bourgoin-Jallieu  
186 (coordinates 45°36'13.9"N, 5°15'31.6" E). Mature individuals were collected and brought to  
187 the laboratory, where they were kept in 30 L aerated tanks filled with groundwater that was  
188 constantly renewed during an acclimatization and stabilization period of 3 weeks. At this  
189 stage, only males were selected and kept in order to avoid potential sensitivity differences  
190 between sexes [50]. Maturity and size homogeneity amongst individuals was also  
191 considered. The light cycle was set to 10 h of light and 14 h of darkness, and the  
192 temperature in the tanks was kept at 12 °C ± 1°C. Gammarids were fed *ad libitum* with alder

193 leaves (*Alnus glutinosa*) that were collected in an unpolluted site and preconditioned  
194 (rehydrated in groundwater during a week approximately).

195

#### 196 **2.4. Experimental set up**

197 Laboratory experiments were carried out in December 2015. Organisms were  
198 exposed to SMX and OXA separately (triplicated experiments for each target compound),  
199 with and without background concentration of surfactants; in both cases, three replicates of  
200 20 male gammarids were exposed for 14 days to a concentration of  $1 \mu\text{g L}^{-1}$  of the  
201 corresponding drug; beakers were filled up with 500 mL of doped groundwater, and the  
202 gammarids were added at the beginning of the experiment. The same procedure was  
203 repeated in parallel, this time adding groundwater doped with a mix of surfactants at a final  
204 concentration of  $25 \mu\text{g L}^{-1}$ . In both cases, the exposed gammarids were fed *ad libitum*. The  
205 experiments were performed in semi-static conditions to avoid aeration in the beakers and  
206 prevent potential degradation of the contaminants. Therefore, and in order to maintain the  
207 same dissolved oxygen (DO) level in the experiments, solutions were made new and  
208 replaced every day with groundwater previously aerated during 24 h. This procedure also  
209 prevented potential bacterial growth in the beakers and adsorption of the pollutants to the  
210 leaves, contributing to keep the same exposure concentration throughout the experiment.  
211 Doping volumes of SMX and OXA were calculated to have a proportion of MeOH  $\leq 0.1 \text{ ‰}$   
212 (v/v) in the solutions. Two sets of blank controls (without PhACs) were also set up in  
213 triplicates: three with only a background concentration of surfactants and the other three  
214 without it. In the latter case, the same amount of MeOH as in the experiments doped with  
215 PhACs was added. All the beakers were placed in a water bath at  $12 \text{ °C} \pm 1 \text{ °C}$ , and submitted  
216 to the same light cycle as used during the acclimatization period.

#### 217 **2.5. Gammarids and water follow up**

218 During the experimental period, gammarids were collected right before the start of  
219 the experiments ( $t_0$ ), then after 1d, 2d, 7d and 14d ( $t_1$ ,  $t_2$ ,  $t_3$  and  $t_4$  respectively). Five  
220 individuals were collected at each sampling time for each set of triplicates, immediately  
221 frozen at  $-80 \text{ °C}$  and finally lyophilized. In the case of the gammarids sampled from the  
222 surfactants experiments, they were previously rinsed in deionized water during two minutes  
223 before freezing. Individuals from both blank controls were also sampled at  $t_3$  and  $t_4$  as  
224 quality controls.

225 In order to check and confirm the PhACs concentration in the solutions, water was  
226 sampled directly from the beakers and analyzed at  $t_2$  and  $t_4$ . Temperature, DO and pH were  
227 monitored every day during the experiment to check for constant conditions. At the end of  
228 the exposure, the remaining gammarids were transferred to new beakers with groundwater  
229 to evaluate their depuration capacity. They were sampled individually after 6h, 24h and 48h.

230

## 231 **2.6. Analytical methodology**

### 232 *2.6.1. HPLC-MS/MS analysis*

233 Both effluent wastewater samples and water samples from the different  
234 experimental tests were analyzed by means of HPLC-MS/MS, working with an Agilent Series  
235 1200 RRLC system (Agilent Technologies, Massy, France) coupled to a 3200 QTrap (ABSciex®,  
236 Les Ulis, France). For surfactants analysis in effluent wastewaters, samples were pretreated  
237 following the methodology of Bergé et al. [51]. Briefly, SPE extraction was carried out using  
238 cartridges Cunax2 (3 cc, 200 mg). A volume of 200 mL of wastewater was loaded onto the  
239 cartridges, and taken to a final reconstitution volume of 2 mL. Further information on the  
240 methodology is given in the Supplementary Information (SI) (Tables S1 and S2).

241 Regarding the water samples from the tests to verify the PhAC concentration during  
242 the experimental period, they did not need any pretreatment (SPE) due to the high working  
243 concentration of the PhACs used and the neglectable amount of suspended solids in the  
244 solutions. An Agilent ZORBAX Eclipse Plus C<sub>18</sub> column was used (50 x 2.1 mm, 1.8  $\mu$ m) with a  
245 mobile phase composition of (a) H<sub>2</sub>O + 0.1% acetic acid and (B) MeOH. The gradient was a  
246 follows: from 10 to 100% (B) in 2 minutes then 100% (B) during 2 minutes and back to initial  
247 conditions in 3 min. The optimization of the MS/MS experimental conditions for SMX and  
248 OXA was performed by direct syringe infusion of standard solutions of the individual  
249 compounds at 10 ng mL<sup>-1</sup>. Identification of the precursor ions was performed in the full scan  
250 mode by recording mass spectra from  $m/z$  50 to 500. Analyses were performed in the  
251 selected reaction monitoring (SRM) mode, recording two SRM transitions per compound,  
252 one for quantitation and the other for positive confirmation. The MS/MS settings are given  
253 in Table S3 (SI).

### 254 *2.6.2. Gammarids analyses*

255 Gammarids were pre-treated and analyzed individually, following and adapting the  
256 method developed by Berlioz-Barbier et al. [23]. Briefly, the sample (1 organism) was placed

257 in a 2 mL centrifuge tube and ground with two stainless steel grinding balls by means of a  
258 2010 Geno/Grinder (SPEX Sample Prep, Stanmore, UK) for 2 min at 1000 spm. Once the  
259 sample was ready, 500  $\mu$ L of milliQ water, 500  $\mu$ L of ACN and 200  $\mu$ L of hexane were added  
260 to the centrifuge tube, followed by the QuEChERS citrate buffer. Tubes were shaken  
261 vigorously to avoid agglomeration of the salts, then vortexed during 30 sec and then  
262 centrifuged during 2 min (10000 rpm). Afterward, hexane was removed and 400  $\mu$ L of ACN  
263 were transferred from the tube to an LC vial, evaporated to dryness under a low N<sub>2</sub> stream  
264 and finally reconstituted to 120  $\mu$ L of H<sub>2</sub>O:ACN:MeOH (70:15:15) for nanoLC-MS/MS  
265 analysis.

### 266 *2.6.3. NanoLC-MS/MS analysis*

267 Analyses were performed on an Ultimate 3000 nanoLC system (ThermoFisher<sup>®</sup>,  
268 Villebon sur Yvette, France) coupled to a 5500 Qtrap (ABSciex<sup>®</sup>, Les Ulis, France) equipped  
269 with a Nanospray II interface (nano-ESI) (ABSciex<sup>®</sup>). Chromatographic separation of SMX and  
270 OXA was achieved by means of an Acclaim C<sub>18</sub> PepMap 100 nanocolumn (5cm x 75  $\mu$ m, 3 $\mu$ m  
271 particle size, 100 Å pore size) preceded by a C<sub>18</sub> PepMap 100  $\mu$ m-pre-column cartridge (5  
272 mm x 300  $\mu$ m, 5  $\mu$ m, 100 Å pore size), both from (ThermoFisher<sup>®</sup>). The auto sampler  
273 temperature was fixed at 5 °C and the column oven was set to 40 °C. An injection volume of  
274 1  $\mu$ L was used in full loop. More information on the methodology can be found elsewhere  
275 [23]. Briefly, the analysis can be divided into two steps. First, a loading step in which the  
276 target compounds are loaded and trapped in the pre-column by means of a loading pump.  
277 The loading solvent used was H<sub>2</sub>O:ACN:MeOH (96:2:2) at a flow rate of 20  $\mu$ L min<sup>-1</sup>. Then, a  
278 separation step when both pre-column and separation column are connected by the switch  
279 of a 10 port-valve (at 1.5 min of the gradient), and the analytes are back-flushed from the  
280 pre-column to the nanoLC column by means of a micropump. The nanoLC flow was 300 nL  
281 min<sup>-1</sup>. Mobile phases and the gradient used are described in Table S4 in SI. The valve  
282 switches again at the end of the gradient (19 min) and the pre-column is put offline, washed  
283 and equilibrated for the next sample. The micro-pump keeps connected to the analytical  
284 column till the end of the gradient.

285 The optimization of the MS/MS experimental conditions was performed as indicated  
286 in section 2.6.1. The nano-ESI source parameters were optimized by on-column injection of  
287 the standards into the chromatographic system.

### 288 *2.6.4. Quantification*

289 Matrix-matched calibration was used for quantification for both water and biota. For  
290 gammarids analysis, ten calibration points were prepared for each experimental set. A pool  
291 of blank gammarids was used, working with individual samples of 5.5 mg (average weight of  
292 an individual gammarid). Each sample was doped with the corresponding concentration of  
293 the PhAC, ranging between the LOQ and 50LOQ, and extracted following the same  
294 procedure as the experimental samples.

295

### 296 **3. RESULTS AND DISCUSSION**

297

#### 298 **3.1. Experimental set up**

##### 299 *3.1.1. Selection of working concentrations for SMX and OXA*

300 Physicochemical properties of both studied compounds are summarized in Table 1.  
301 Given the high number of publications dealing with PhACs presence in wastewaters and  
302 surface waters, a bibliographic research was carried out in order to know the usual  
303 concentrations detected for SMX and OXA and choose a representative dope level. A  
304 summary is given in Table S5 (SI).

305 SMX is one of the most ubiquitous antibiotics, being frequently detected in all water  
306 ecosystems probably due to its solubility and high excretion rates [52-54]. Its environmental  
307 occurrence and fate has been studied intensively due to its potential, even at low  
308 concentrations, to promote antibiotic resistance [55, 56]. Concentrations in urban WWTP  
309 effluents can range from 10 ng L<sup>-1</sup> to 650 ng L<sup>-1</sup> [52] and up to 8714 ng L<sup>-1</sup> in hospital  
310 effluents [57]. In surface waters, average concentrations of 89.2 ng L<sup>-1</sup> were detected in the  
311 Ebro river basin in Spain [52], and up to 653 ng L<sup>-1</sup> in the Llobregat river mouth [58]. There is  
312 still a huge uncertainty regarding the biodegradability of SMX during wastewater treatment,  
313 considering that published removal rates range from negative values to 100% elimination  
314 [59]. once released in surface waters, its elimination depends on the presence of  
315 appropriate degrading microorganisms. Photodegradation may have a role in its elimination,  
316 but only to a small extent and in the most superficial water layers.

317 On the other hand, OXA is a psychiatric drug belonging to the group of  
318 benzodiazepines (anxiolytics). It is also the final degradation product of diazepam, one of the  
319 most consumed antidepressant worldwide [60]. Loos et al. [61] found out that oxazepam was  
320 present in the 90% of the 90 effluent samples analyzed in 18 different European countries,  
321 at an average concentration of 162 ng L<sup>-1</sup>. Similar results were detected by Baker et al. [62]

322 in the UK . Furthermore, it has been demonstrated that OXA is resilient not only to aerobic  
323 and anaerobic biodegradation, but also to photodegradation [60, 63] and so it is likely that  
324 this compound can persist and bioaccumulate in aquatic ecosystems. Klaminder et al. [64]  
325 concluded that OXA could persist in water systems for decades.

326 The working concentration of both compounds was finally set at  $1 \mu\text{g L}^{-1}$  to allow the  
327 evaluation of bioaccumulation and also to make possible future metabolite elucidation  
328 analyses.

### 329 *3.1.2. Selection of working concentrations for surfactants*

330 Levels of surfactants detected in the effluent wastewater sampled are shown in  
331 Table 2. As observed, the concentrations ranged from  $0.13 \mu\text{g L}^{-1}$  to  $34.2 \mu\text{g L}^{-1}$ . The highest  
332 concentrations corresponded to the anionic surfactants LAS C<sub>10-13</sub>, specifically to LAS C<sub>12</sub>  
333 ( $34.2 \mu\text{g L}^{-1}$ ). Similar and usually higher concentrations in effluent wastewaters are found in  
334 the literature [43, 51]. A working concentration of  $25 \mu\text{g L}^{-1}$  was finally selected as  
335 representative of a real scenario.

336

## 337 **3.2. Exposure experiments**

338 Only the free dissolved concentration in water of a given compound is bioavailable  
339 and can pass through biological membranes [65]. The use of groundwater in the  
340 experiments, containing negligible amounts of suspended solids, ensured that none of the  
341 spiked drugs were sorbed or bound to these particles, and so all the pollutant was available  
342 for potential bioconcentration in the test organisms. Working at semi-static conditions aided  
343 to renew the media and the available concentration on a daily basis, avoiding any potential  
344 degradation during the 14 d exposure. Furthermore, the information provided in section  
345 3.1.1 also confirms the resilience of both PhACs in water environment in short-term  
346 experiments.

347 The concentration of both compounds in the water from the different beakers was  
348 measured twice (once per week) during the experiment (Table 3). Variation between both  
349 weeks was negligible for OXA (0.7%-4.4%) and low for SMX (9.9%-13%). Other control  
350 parameters such as pH, DO and T were also measured (see S.I., Table S6 ).

351 Regarding nano-LC-MS/MS analyses, the methodology used allowed the analysis at  
352 individual scale for five gammarids individuals per day of sampling. Inter-individual  
353 variability was estimated as the relative standard deviation (RSD) and is shown in Table S7

354 (SI). No background concentration was detected in any of the individuals from the blank  
355 controls.

### 356 3.2.1. Mortality

357 After one week of exposure, the mortality of gammarids stayed below 30% in both  
358 controls (with and without surfactants). The overall mortality at the end of the experiment  
359 was of 35% of the individuals in the control without surfactants and a 20% in the control  
360 with the surfactants mixture (see Figure 1). Micelles formed by the surfactants may have a  
361 protective function against external conditions for the gammarids; for instance, against the  
362 doped MeOH that was added in both controls to equal the amount of PhACs added in the  
363 rest of the experiments (despite it remained  $\leq 0.1 \text{ ‰ (v/v)}$  in all the solutions).  
364 Unfortunately, there are currently no standard exposure tests for gammarids. Different  
365 publications put forward a cut-off level of 10% mortality in the blank controls, as quality  
366 measure [66, 67]. However, it should be taken into account that the exposure conditions in  
367 these papers were different to those in our work; for instance, the exposure was shorter (10  
368 d), the gammarids were not fed, and the species used (*Gammarid pulex*) and population  
369 origin were completely different. Nevertheless, considering the proposed threshold,  
370 mortality was highly acceptable at least in the control with surfactants after 10 d (11.6%). On  
371 the other hand, for other sensitive crustaceans such as daphnia, test validity is fixed to 20%  
372 of mortality in the controls (for exposures of 7 days, ISO (2008) International Standard  
373 20665). In our experiment, this 20% mortality is reached after 14 days of exposure in the  
374 control with surfactants, but it was reached after only 4 days in the control without  
375 surfactants. This could also be due to a lack of homogeneity of the individuals: differences in  
376 age and degree of maturity (despite the selection was done carefully), tolerance to the  
377 organic matter in the beakers (although the containers were cleaned and refilled daily), or  
378 some errors during the manipulation of the beakers.

379 In the experiments without surfactants, SMX showed a rapid increase in the  
380 mortality rate, reaching 23% after the first week, and 28% at the end of the experiment,  
381 with an average of 14 survivors out of 20 in each triplicate experiment (no considering the  
382 individuals sampled) (see Figure 1a). The mortality registered in the experiments with OXA  
383 was slightly lower, with a 15% of mortality after a week and a final mortality of 22% at the  
384 end of the experiment (average of 16 survivors in each triplicate). The potential adverse  
385 effects of SMX in the gammarids acted more rapidly than those of OXA during the 14 days of  
386 exposure. To the author's knowledge, there are no data regarding the ecotoxicity of SMX  
387 against benthic invertebrates. The most restrictive ecotoxicity values found in the literature

388 are half maximal effective concentrations ( $EC_{50}$ ) of  $27 \mu\text{g L}^{-1}$  against blue green algae and up  
389 to  $25.2 \text{ mg L}^{-1}$  against daphnids [68]. In both cases, these  $EC_{50}$  values are much higher than  
390 the concentration used in the experiments in this study ( $1 \mu\text{g L}^{-1}$ ). Regarding OXA, its  
391 ecotoxicity is poorly described in the literature. There is only one published study from 1994  
392 by Calleja et al. [69], in which the hazard quotient for this compound was estimated  
393 considering the environmental measured concentrations (MECs), resulting in “unlikely risk”.  
394 More recently, Brody et al. [70] observed behavioural alterations in wild European perch  
395 exposed to  $1.8 \mu\text{g L}^{-1}$  of this drug.

396 In contrast, the mortality rate was higher in both exposure experiments of OXA and  
397 SMX with background concentration of surfactants, and equal to 33.3% in both cases at the  
398 end of the experiments (with an average of 13 survivors out of 20 in each triplicate). This  
399 could be explained in terms of the additive effect of the background concentration of the  
400 surfactants. As observed in Figure 1b, the mortality was higher in the PhACs doped  
401 experiments than in the corresponding control, more markedly during the second week. It  
402 seems that the extended exposure to surfactants had an effect on the vulnerability of these  
403 organisms to other external factors, in this case SMX or OXA simultaneously present in the  
404 same media. However, this is not reflected in an increased bioconcentration of SMX or OXA  
405 in the organisms (see section 3.3).

#### 406 *3.2.2. Feeding test*

407 Due to the low number of survivors by the end of the experiments, feed tests could  
408 only be carried out in both control experiments (with and without detergents), in order to  
409 check if the background presence of surfactants, independently from the effects of the  
410 studied PhACs, affected the efficiency of gammarids as CPOM shredders. The feeding rate is  
411 frequently used as a sensitive and robust endpoint in bioassays, indicating relevant changes  
412 in the equilibrium of fresh water ecosystems [71].

413 At the end of the experiments, the remaining food was removed from the beakers and 10  
414 leaf discs were added in each replicate of the controls. An average of 10 gammarids  
415 remained in the control without surfactants, and 13 in the controls with the surfactant  
416 concentration. Differences were not very significant, as feeding was only slightly higher in  
417 those controls with a background concentration of surfactants (5.9% higher), which could be  
418 attributed to stress in the organisms (see Figure S1 in SI).

419

#### 420 **3.3. Exposure over time and bioconcentration**

421 In all the experimental sets, 5 organisms were taken at each sampling time and  
422 analyzed. Detected values were above LOQ in all cases. With the results obtained, kinetic  
423 curves were built by means of the SciDAVIs free software, using the Levenberg-Marquardt  
424 algorithm [72].

### 425 3.3.1. Oxazepam

426 Figure 2 shows the bioconcentration kinetic curves of OXA in the gammarids. In the  
427 experiment without surfactants (exposure  $1\mu\text{g L}^{-1}$ ), an increasing trend was observed from  
428 the beginning, which was strong during the first day, going from 0 to an average value of  
429  $50.2\text{ ng g}^{-1}$  after only 24 h. After that, the concentration in the organisms kept accumulating  
430 but at a more moderate pace. At the end of the experiment, the steady state hadn't been  
431 achieved, and an average concentration of  $106\text{ ng g}^{-1}$  was detected in the organisms. Sordet  
432 et al. [21] carried out a similar experiment with a lower concentration exposure to the drug  
433 ( $200\text{ ng L}^{-1}$ ). This resulted in a much slower bioconcentration process, reaching an average  
434 value of  $2.73\text{ ng g}^{-1}$  after 1 day. It decreased at day 2 ( $2.03\text{ ng g}^{-1}$ ), but kept increasing till day  
435 7 ( $3.98\text{ ng g}^{-1}$ ). Steady state was achieved during the second week, and the bioconcentration  
436 started decreasing from day 14 on. Comparison with this previous study shows that the  
437 capacity of gammarids to accumulate OXA could be proportional to the exposure  
438 concentration. If we look at the kinetic curve estimated in the present study, it seems that  
439 the bioconcentration plateau was reached between day 4 and 6 of exposure. The mortality  
440 associated to that first week of exposure went up to 15%, higher than the mortality  
441 registered from that point till the end of the experiment (from 15% to 22%).

442 Lagesson et al. [19] found out bioaccumulation concentrations around  $10\text{ ng g}^{-1}$  in different  
443 benthic invertebrates such as *Ephemeroptera sp.* or *Zygoptera sp.* in a natural pond spiked  
444 at an initial concentration of  $400\text{ ng L}^{-1}$ . Despite the potential decrease in the water  
445 concentration with time, it barely affected the bioaccumulation levels during the length of  
446 the experiment (65 days).

447 In the experiment with the background concentration of surfactants, the trend was  
448 similar during the first week, reaching body burdens around  $74\text{-}76\text{ ng g}^{-1}$ . Bioconcentration  
449 of OXA reached  $33.7\text{ ng g}^{-1}$  after one day (compared to the  $50\text{ ng g}^{-1}$  in the experiment  
450 without surfactants). Between days 2 and 7 of the experiment, average concentrations went  
451 from  $47.5\text{ ng g}^{-1}$  to  $74.03\text{ ng g}^{-1}$  (an increase of 55.7%). It correlates with a quick increase in  
452 the mortality during the first week (25% on day 7). Between days 7 and 14, the  
453 bioconcentration decreased a 12%, reaching an average value of  $65\text{ ng g}^{-1}$ , suggesting that

454 the steady state would have been achieved during the last days of the experiment and after  
455 that, a depuration process would have started. In contrast, mortality was higher during the  
456 first week (25%) and increased during that last week, but a much lower pace, reaching a final  
457 value of 33% of dead individuals. As observed, the body burden of the gammarids in this  
458 case could have been diminished by the presence of surfactants, which seem to decrease  
459 the capacity of gammarids to accumulate this drug. Contrary to what was expected, the  
460 presence of surfactants may have some effect on the physiology of gammarids, as mortality  
461 was higher at the end of this experiment but the bioconcentration of OXA was lower (see  
462 Figure 1b and 2b).

### 463 *3.3.2. Sulfamethoxazole*

464 Regarding SMX, bioconcentration kinetics followed a different trend (see Figure 3).  
465 In the experiment without surfactants, bioaccumulation was observed from the beginning of  
466 the experiment but at a much slower rate than that of OXA ( $18 \text{ ng g}^{-1}$  on day 1); it did not  
467 vary on day 2 and then increased during the rest of the experiment, reaching  $44.4 \text{ ng g}^{-1}$   
468 after two weeks (see Figure 3a). In this case, the mortality increased rapidly during the first  
469 week, reaching a 23% at day 7, and then increased to a final value of 28% during the second  
470 week (Figure 1a).

471 In the experiment with surfactants, it can be observed that the average  
472 concentration detected in the organisms was nearly the same from the first day till the end  
473 of the experiment, indicating that the steady state was reached between day 1 and 2 at a  
474 concentration around  $9 \text{ ng g}^{-1}$  (see Figure 3b). Mortality reached a 10% on day 3 and  
475 remained stable till day 6 and increasing much more markedly during the second week (see  
476 Figure 1b). As observed with OXA, it seemed that the background presence of the  
477 surfactants mix decreased the bioconcentration rate of the antibiotic but enhanced the  
478 mortality rate throughout the experiment, especially during the second week. These results  
479 diverge with those observed in the experiment with OXA, in which mortality was more  
480 severe during the first week of exposure. Nevertheless, differences in the bioconcentration  
481 amount between OXA and SMX could be attributed to a higher solubility of the antibiotic,  
482 making it less prone to accumulate in the gammarid tissues. This could also explain why the  
483 background presence of surfactants hampered the bioaccumulation of SMX in comparison  
484 with the exposure experiments without that mix (four times fold).

### 485 *3.3.3. Bioconcentration factor*

486 The bioconcentration factor (BCF) reflects that capacity of the organism to  
487 accumulate a given compound from the environment, but only through its respiratory and  
488 dermal surfaces (exposure in the diet is excluded) [65]. It can be calculated following  
489 equation 1:

490 [1]

$$\frac{dC_{organism}}{dt} = k_{in} \times C_w(t) - k_{out} \times C_{organism}(t)$$

491 where t is time,  $C_{organism}$  is the concentration in the organism,  $k_{in}$  is the uptake rate constant  
492 from the water ( $\text{mL g}^{-1} \text{d}^{-1}$ ),  $C_w$  the concentration in the water and  $k_{out}$  is the depuration rate  
493 constant ( $\text{d}^{-1}$ ), which gathers different elimination pathways in the organism such as  
494 respiratory surface, fecal egestion, metabolic biotransformation and/or growth dilution [73].  
495  $k_{in}$  and  $k_{out}$  are given in Table 4 and were estimated by the SciDAVis software, considering  
496 first order kinetics described with a one-compartment toxicokinetic model [74]. Only when  
497  $C_{organism}$  and  $C_w$  do not change with time, the system has reached the steady state condition  
498 and BCF can be calculated as follows (equation [2]):

499 [2]

$$\frac{k_{in}}{k_{out}} = \frac{C_{org}}{C_w} = BCF$$

500

501 Steady state was reached only in two of the four experiments.

502 Following the indications from REACH legislation, those compounds with a BCF >  
503 2000 are considered bioaccumulative, and very bioaccumulative if the corresponding BCF >  
504 5000. Despite BCFs are higher for OXA than for SMX, both are far below these threshold  
505 limits established by the UE.

506

### 507 **3.4. Depuration experiments**

508

509 At the end of the exposure experiments, survivors were placed in beakers with  
510 groundwater during 72 hours to evaluate their depuration capacity. The limiting factor in  
511 this case was the number of survivors at the end of each experiment, and the evaluation  
512 could only be carried out after the exposure experiments for OXA without surfactants, with  
513 a total of 6 gammarids in the three bakers. As shown in Figure 4, depuration of OXA

514 happened quickly, as levels decreased from 105.4 ng g<sup>-1</sup> to 50 ng g<sup>-1</sup> in barely 6 h, and it was  
515 fully eliminated before 72 h. Data seemed to follow and first order exponential decay.

516 Only 4 gammarids survived in both SMX experiments, and after only 6 h, no trace of  
517 sulfamethoxazole could be detected. There were no survivors in the experiment with OXA  
518 and surfactants.

519

#### 520 **4. CONCLUSIONS**

521

522 The structural and functional equilibrium of freshwater ecosystems is currently  
523 compromised by the environmental presence of a large number of organic pollutants which  
524 are being discharged into natural waters on a regular basis. Data on this regard is still  
525 insufficient for a full risk assessment, particularly on the direct or indirect effects of mixtures  
526 of these contaminants in the first trophic levels. Bibliographic research demonstrates that  
527 uptake data available for aquatic organisms is mostly devoted to fish and aquatic plants.  
528 Recent works have shown the bioaccumulation of selected pharmaceuticals in gammarids,  
529 but have not fully addressed their bioconcentration kinetics. This work demonstrates the  
530 highest capacity of gammarids to accumulate OXA than SMX at the same exposure  
531 conditions, even under environmental stress situations such as the background presence of  
532 other contaminants, and also their capacity to quickly eliminate one of these compounds,  
533 OXA, from their tissues. Mortality registered was higher in the exposure experiments with  
534 surfactants ( 33% vs 28% after 14 d). Bioconcentration of OXA was more relevant than that  
535 of SMX in both experiments with and without the presence of surfactants. Further studies  
536 will focus on the gammarids metabolism of the bioconcentrated PhACs, in order to evaluate  
537 to which extent metabolism is key in the elimination of this compounds and which TPs are  
538 generated.

539

#### 540 **ACKNOWLEDGMENTS**

541 Maria Jesús Garcia would like to thank the Catalan Government for her research  
542 grant (2014 BP-A 00245) and to the Spanish Ministry of Industry and Economy for her  
543 financial support (FJCI-2014-22767).

544

545

546 REFERENCES

547

- 548 1. Li, W.C., *Occurrence, sources, and fate of pharmaceuticals in aquatic environment*  
549 *and soil*. Environmental Pollution, 2014. **187**: p. 193-201.
- 550 2. Koba, O., et al., *Transformation of atenolol, metoprolol, and carbamazepine in*  
551 *soils: The identification, quantification, and stability of the transformation*  
552 *products and further implications for the environment*. Environmental Pollution,  
553 2016.
- 554 3. Fatta-Kassinos, D., S. Meric, and A. Nikolaou, *Pharmaceutical residues in*  
555 *environmental waters and wastewater: Current state of knowledge and future*  
556 *research*. Analytical and Bioanalytical Chemistry, 2011. **399**(1): p. 251-275.
- 557 4. Kümmerer, K., *The presence of pharmaceuticals in the environment due to human*  
558 *use – present knowledge and future challenges*. Journal of Environmental  
559 Management, 2009. **90**(8): p. 2354-2366.
- 560 5. Ginebreda, A., et al., *Environmental risk assessment of pharmaceuticals in rivers:*  
561 *Relationships between hazard indexes and aquatic macroinvertebrate diversity*  
562 *indexes in the Llobregat River (NE Spain)*. Environment International, 2010.  
563 **36**(2): p. 153-162.
- 564 6. Gros, M., et al., *Removal of pharmaceuticals during wastewater treatment and*  
565 *environmental risk assessment using hazard indexes*. Environment International,  
566 2010. **36**(1): p. 15-26.
- 567 7. Langdon, K.A., M.S.T.J. Warne, and R.S. Kookanaz, *Aquatic hazard assessment for*  
568 *pharmaceuticals, personal care products, and endocrine-disrupting compounds*  
569 *from biosolids-amended land*. Integrated Environmental Assessment and  
570 Management, 2010. **6**(4): p. 663-676.
- 571 8. Park, S. and K. Choi, *Hazard assessment of commonly used agricultural antibiotics*  
572 *on aquatic ecosystems*. Ecotoxicology, 2008. **17**(6): p. 526-538.
- 573 9. Ruhí, A., et al., *Bioaccumulation and trophic magnification of pharmaceuticals and*  
574 *endocrine disruptors in a Mediterranean river food web*. Science of The Total  
575 Environment, 2016. **540**: p. 250-259.
- 576 10. Silva, L.J.G., et al., *Reviewing the serotonin reuptake inhibitors (SSRIs) footprint in*  
577 *the aquatic biota: Uptake, bioaccumulation and ecotoxicology*. Environmental  
578 Pollution, 2015. **197**: p. 127-143.
- 579 11. Ding, J., G. Lu, and Y. Li, *Interactive effects of selected pharmaceutical mixtures on*  
580 *bioaccumulation and biochemical status in crucian carp (Carassius auratus)*.  
581 Chemosphere, 2016. **148**: p. 21-31.
- 582 12. Valdés, M.E., et al., *Bioaccumulation and bioconcentration of carbamazepine and*  
583 *other pharmaceuticals in fish under field and controlled laboratory experiments.*  
584 *Evidences of carbamazepine metabolization by fish*. Science of The Total  
585 Environment, 2016. **557–558**: p. 58-67.
- 586 13. Li, S.-W. and A.Y.-C. Lin, *Increased acute toxicity to fish caused by pharmaceuticals*  
587 *in hospital effluents in a pharmaceutical mixture and after solar irradiation*.  
588 Chemosphere, 2015. **139**: p. 190-196.

- 589 14. Valdés, M.E., et al., *Occurrence and bioaccumulation of pharmaceuticals in a fish*  
590 *species inhabiting the Suquía River basin (Córdoba, Argentina)*. *Science of The*  
591 *Total Environment*, 2014. **472**: p. 389-396.
- 592 15. Huerta, B., et al., *Analysis of multi-class pharmaceuticals in fish tissues by ultra-*  
593 *high-performance liquid chromatography tandem mass spectrometry*. *Journal of*  
594 *Chromatography A*, 2013. **1288**: p. 63-72.
- 595 16. Madureira, T.V., et al., *The toxicity potential of pharmaceuticals found in the*  
596 *Douro River estuary (Portugal): Evaluation of impacts on fish liver, by*  
597 *histopathology, stereology, vitellogenin and CYP1A immunohistochemistry, after*  
598 *sub-acute exposures of the zebrafish model*. *Environmental Toxicology and*  
599 *Pharmacology*, 2012. **34**(1): p. 34-45.
- 600 17. Huerta, B., et al., *Development of an extraction and purification method for the*  
601 *determination of multi-class pharmaceuticals and endocrine disruptors in*  
602 *freshwater invertebrates*. *Talanta*, 2015. **132**: p. 373-381.
- 603 18. Grabicova, K., et al., *Presence of pharmaceuticals in benthic fauna living in a small*  
604 *stream affected by effluent from a municipal sewage treatment plant*. *Water*  
605 *Research*, 2015. **72**: p. 145-153.
- 606 19. Lagesson, A., et al., *Bioaccumulation of five pharmaceuticals at multiple trophic*  
607 *levels in an aquatic food web - Insights from a field experiment*. *Science of The*  
608 *Total Environment*, 2016. **568**: p. 208-215.
- 609 20. Maltby, L., *Stress, shredders and streams: using gammarus energetics to assess*  
610 *water quality*. In: *Sutcliffe, D.W. (ed.) Water quality & stress indicators in marine*  
611 *and freshwater systems: linking levels of organisation*. *Ambleside, UK, Freshwater*  
612 *Biological Association*, pp. 98-110. . 1994.
- 613 21. Sordet, M., et al., *Quantification of emerging micropollutants in an amphipod*  
614 *crustacean by nanoliquid chromatography coupled to mass spectrometry using*  
615 *multiple reaction monitoring cubed mode*. *Journal of Chromatography A*, 2016.  
616 **1456**: p. 217-225.
- 617 22. Miller, T.H., et al., *Pharmaceuticals in the freshwater invertebrate, Gammarus*  
618 *pulex, determined using pulverised liquid extraction, solid phase extraction and*  
619 *liquid chromatography-tandem mass spectrometry*. *Science of The Total*  
620 *Environment*, 2015. **511**: p. 153-160.
- 621 23. Berlioz-Barbier, A., et al., *Multi-residue analysis of emerging pollutants in benthic*  
622 *invertebrates by modified micro-quick-easy-cheap-efficient-rugged-safe extraction*  
623 *and nanoliquid chromatography-nanospray-tandem mass spectrometry analysis*.  
624 *Journal of Chromatography A*, 2014. **1367**: p. 16-32.
- 625 24. Forrow, D.M. and L. Maltby, *Toward a mechanistic understanding of contaminant-*  
626 *induced changes in detritus processing in streams: Direct and indirect effects on*  
627 *detritivore feeding*. *Environmental Toxicology and Chemistry*, 2000. **19**(8): p.  
628 2100-2106.
- 629 25. De Lange, H.J., et al., *Behavioural responses of Gammarus pulex (Crustacea,*  
630 *Amphipoda) to low concentrations of pharmaceuticals*. *Aquatic Toxicology*, 2006.  
631 **78**(3): p. 209-216.
- 632 26. Fatta-Kassinos, D., M.I. Vasquez, and K. Kümmerer, *Transformation products of*  
633 *pharmaceuticals in surface waters and wastewater formed during photolysis and*  
634 *advanced oxidation processes - Degradation, elucidation of byproducts and*  
635 *assessment of their biological potency*. *Chemosphere*, 2011. **85**(5): p. 693-709.

- 636 27. Osorio, V., et al., *Simultaneous determination of diclofenac, its human metabolites*  
637 *and microbial nitration/nitrosation transformation products in wastewaters by*  
638 *liquid chromatography/quadrupole-linear ion trap mass spectrometry.* Journal of  
639 Chromatography A, 2014. **1347**: p. 63-71.
- 640 28. Heuett, N.V., S.R. Batchu, and P.R. Gardinali, *Understanding the magnitude of*  
641 *emergent contaminant releases through target screening and metabolite*  
642 *identification using high resolution mass spectrometry: Illicit drugs in raw sewage*  
643 *influent.* Journal of Hazardous Materials, 2015. **282**: p. 41-50.
- 644 29. Hübner, U., U. von Gunten, and M. Jekel, *Evaluation of the persistence of*  
645 *transformation products from ozonation of trace organic compounds – A critical*  
646 *review.* Water Research, 2015. **68**: p. 150-170.
- 647 30. Donner, E., et al., *Ecotoxicity of carbamazepine and its UV photolysis*  
648 *transformation products.* Science of the Total Environment, 2013. **443**: p. 870-  
649 876.
- 650 31. García-Galán, M.J., et al., *Biodegradation of sulfamethazine by Trametes versicolor:*  
651 *Removal from sewage sludge and identification of intermediate products by UPLC-*  
652 *QqTOF-MS.* Science of the Total Environment. **409**(24): p. 5505-5512.
- 653 32. García-Galán, M.J., et al., *Advanced oxidation of the antibiotic sulfapyridine by*  
654 *UV/H<sub>2</sub>O<sub>2</sub>: Characterization of its transformation products and ecotoxicological*  
655 *implications.* Chemosphere, 2016. **147**: p. 451-459.
- 656 33. García-Galán, M.J., et al., *UV/H<sub>2</sub>O<sub>2</sub> degradation of the antidepressants venlafaxine*  
657 *and O-desmethylvenlafaxine: Elucidation of their transformation pathway and*  
658 *environmental fate.* Journal of Hazardous Materials, 2016. **311**: p. 70-80.
- 659 34. Villa, S., M. Vighi, and A. Finizio, *Experimental and predicted acute toxicity of*  
660 *antibacterial compounds and their mixtures using the luminescent bacterium*  
661 *Vibrio fischeri.* Chemosphere, 2014. **108**: p. 239-244.
- 662 35. Clevers, M., *Mixture toxicity of the anti-inflammatory drugs diclofenac, ibuprofen,*  
663 *naproxen, and acetylsalicylic acid.* Ecotoxicology and Environmental Safety, 2004.  
664 **59**(3): p. 309-315.
- 665 36. Trombini, C., M. Hampel, and J. Blasco, *Evaluation of acute effects of four*  
666 *pharmaceuticals and their mixtures on the copepod Tisbe battagliai.*  
667 Chemosphere, 2016. **155**: p. 319-328.
- 668 37. Geiger, E., R. Hornek-Gausterer, and M.T. Saçan, *Single and mixture toxicity of*  
669 *pharmaceuticals and chlorophenols to freshwater algae Chlorella vulgaris.*  
670 Ecotoxicology and Environmental Safety, 2016. **129**: p. 189-198.
- 671 38. Ding, J., et al., *Uptake, depuration, and bioconcentration of two pharmaceuticals,*  
672 *roxithromycin and propranolol, in Daphnia magna.* Ecotoxicology and  
673 Environmental Safety, 2016. **126**: p. 85-93.
- 674 39. Agency, E.C. *Regulation (EC) No 1907/2006 of the European Parliament and of*  
675 *the Council on the Registration, Evaluation, Authorisation and Restriction of*  
676 *Chemicals (REACH) 2006; Available from:*  
677 <https://echa.europa.eu/es/regulations/reach/legislation>.
- 678 40. Ying, G.-G., *Fate, behavior and effects of surfactants and their degradation*  
679 *products in the environment.* Environment International, 2006. **32**(3): p. 417-  
680 431.

- 681 41. Lara-Martín, P.A., A. Gómez-Parra, and E. González-Mazo, *Reactivity and fate of*  
682 *synthetic surfactants in aquatic environments*. TrAC Trends in Analytical  
683 Chemistry, 2008. **27**(8): p. 684-695.
- 684 42. González, S., M. Petrovic, and D. Barceló, *Evaluation of two pilot scale membrane*  
685 *bioreactors for the elimination of selected surfactants from municipal*  
686 *wastewaters*. Journal of Hydrology, 2008. **356**(1-2): p. 46-55.
- 687 43. González, S., D. Barceló, and M. Petrovic, *Advanced liquid chromatography-mass*  
688 *spectrometry (LC-MS) methods applied to wastewater removal and the fate of*  
689 *surfactants in the environment*. TrAC Trends in Analytical Chemistry, 2007.  
690 **26**(2): p. 116-124.
- 691 44. Laha, S., B. Tansel, and A. Ussawarujikulchai, *Surfactant-soil interactions during*  
692 *surfactant-amended remediation of contaminated soils by hydrophobic organic*  
693 *compounds: A review*. Journal of Environmental Management, 2009. **90**(1): p. 95-  
694 100.
- 695 45. Kile, D.E. and C.T. Chiou, *Water solubility enhancements of DDT and*  
696 *trichlorobenzene by some surfactants below and above the critical micelle*  
697 *concentration*. Environmental Science & Technology, 1989. **23**(7): p. 832-838.
- 698 46. Katagi, T., *Surfactant Effects on Environmental Behavior of Pesticides in Reviews of*  
699 *Environmental Contamination and Toxicology*. 2008, Springer: Heidelberg, New  
700 York. p. 71-158.
- 701 47. Qiao, X., et al., *Faster photodegradation rate and higher dioxin yield of triclosan*  
702 *induced by cationic surfactant CTAB*. Journal of Hazardous Materials, 2014. **275**:  
703 p. 210-214.
- 704 48. Oleszczuk, P., I. Joško, and E. Skwarek, *Surfactants decrease the toxicity of ZnO,*  
705 *TiO<sub>2</sub> and Ni nanoparticles to Daphnia magna*. Ecotoxicology, 2015. **24**(9): p.  
706 1923-1932.
- 707 49. Barrena, R., et al., *Evaluation of the ecotoxicity of model nanoparticles*.  
708 Chemosphere, 2009. **75**(7): p. 850-857.
- 709 50. Sornom, P., et al., *Effect of gender on physiological and behavioural responses of*  
710 *Gammarus roeseli (Crustacea Amphipoda) to salinity and temperature*.  
711 Environmental Pollution, 2010. **158**(5): p. 1288-1295.
- 712 51. Alexandre, B., et al., *Development of a multiple-class analytical method based on*  
713 *the use of synthetic matrices for the simultaneous determination of commonly used*  
714 *commercial surfactants in wastewater by liquid chromatography-tandem mass*  
715 *spectrometry*. Journal of Chromatography A, 2016. **1450**: p. 64-75.
- 716 52. García-Galán, M.J., M.S. Díaz-Cruz, and D. Barceló, *Occurrence of sulfonamide*  
717 *residues along the Ebro river basin. Removal in wastewater treatment plants and*  
718 *environmental impact assessment*. Environment International, 2011. **37**(2): p.  
719 462-473.
- 720 53. Gros, M., S. Rodríguez-Mozaz, and D. Barceló, *Fast and comprehensive multi-*  
721 *residue analysis of a broad range of human and veterinary pharmaceuticals and*  
722 *some of their metabolites in surface and treated waters by ultra-high-performance*  
723 *liquid chromatography coupled to quadrupole-linear ion trap tandem mass*  
724 *spectrometry*. Journal of Chromatography A, 2012. **1248**: p. 104-121.
- 725 54. García-Galán, M.J., et al., *Multiresidue trace analysis of pharmaceuticals, their*  
726 *human metabolites and transformation products by fully automated on-line solid-*

- 727 *phase extraction-liquid chromatography-tandem mass spectrometry*. *Talanta*,  
728 2016. **158**: p. 330-341.
- 729 55. Huerta, B., et al., *Exploring the links between antibiotic occurrence, antibiotic*  
730 *resistance, and bacterial communities in water supply reservoirs*. *Science of The*  
731 *Total Environment*, 2013. **456-457**: p. 161-170.
- 732 56. Marti, E., E. Variatza, and J.L. Balcazar, *The role of aquatic ecosystems as reservoirs*  
733 *of antibiotic resistance*. *Trends in Microbiology*, 2014. **22**(1): p. 36-41.
- 734 57. Santos, L.H.M.L.M., et al., *Contribution of hospital effluents to the load of*  
735 *pharmaceuticals in urban wastewaters: Identification of ecologically relevant*  
736 *pharmaceuticals*. *Science of The Total Environment*, 2013. **461-462**: p. 302-316.
- 737 58. Garc a-Gal n, M.J., et al., *LC-QqLIT MS analysis of nine sulfonamides and one of*  
738 *their acetylated metabolites in the Llobregat River basin. Quantitative*  
739 *determination and qualitative evaluation by IDA experiments*. *Analytical and*  
740 *Bioanalytical Chemistry*. **397**(3): p. 1325-1334.
- 741 59. Straub, J.O., *Aquatic environmental risk assessment for human use of the old*  
742 *antibiotic sulfamethoxazole in Europe*. *Environmental Toxicology and Chemistry*,  
743 2016. **35**(4): p. 767-779.
- 744 60. Kosjek, T., et al., *Environmental occurrence, fate and transformation of*  
745 *benzodiazepines in water treatment*. *Water Research*, 2012. **46**(2): p. 355-368.
- 746 61. Loos, R., et al., *EU-wide monitoring survey on emerging polar organic*  
747 *contaminants in wastewater treatment plant effluents*. *Water Research*, 2013.  
748 **47**(17): p. 6475-6487.
- 749 62. Baker, D.R. and B. Kasprzyk-Hordern, *Multi-residue analysis of drugs of abuse in*  
750 *wastewater and surface water by solid-phase extraction and liquid*  
751 *chromatography-positive electrospray ionisation tandem mass spectrometry*.  
752 *Journal of Chromatography A*, 2011. **1218**(12): p. 1620-1631.
- 753 63. Calisto, V., M.R.M. Domingues, and V.I. Esteves, *Photodegradation of psychiatric*  
754 *pharmaceuticals in aquatic environments – Kinetics and photodegradation*  
755 *products*. *Water Research*, 2011. **45**(18): p. 6097-6106.
- 756 64. Klaminder, J., et al., *Long-Term Persistence of an Anxiolytic Drug (Oxazepam) in a*  
757 *Large Freshwater Lake*. *Environmental Science and Technology*, 2015. **49**(17): p.  
758 10406-10412.
- 759 65. Arnot, J.A. and F.A.P.C. Gobas, *A review of bioconcentration factor (BCF) and*  
760 *bioaccumulation factor (BAF) assessments for organic chemicals in aquatic*  
761 *organisms*. *Environmental Reviews*, 2006. **14**(4): p. 257-297.
- 762 66. Vellinger, C., et al., *Comparison of arsenate and cadmium toxicity in a freshwater*  
763 *amphipod (Gammarus pulex)*. *Environmental Pollution*, 2012. **160**: p. 66-73.
- 764 67. Vellinger, C., et al., *Single and combined effects of cadmium and arsenate in*  
765 *Gammarus pulex (Crustacea, Amphipoda): Understanding the links between*  
766 *physiological and behavioural responses*. *Aquatic Toxicology*, 2013. **140-141**: p.  
767 106-116.
- 768 68. Garc a-Gal n, M.J., et al., *Ecotoxicity evaluation and removal of sulfonamides and*  
769 *their acetylated metabolites during conventional wastewater treatment*. *Science*  
770 *of the Total Environment*, 2012. **437**: p. 403-412.
- 771 69. Calleja, M.C., P. Geladi, and G. Persoone, *Modelling of human acute toxicity from*  
772 *physicochemical properties and non-vertebrate acute toxicity of the 38 organic*

773 *chemicals of the MEIC priority list by PLS regression and neural network.* Food and  
774 Chemical Toxicology, 1994. **32**(10): p. 923-941.

775 70. Brodin, T., et al., *Dilute concentrations of a psychiatric drug alter behavior of fish*  
776 *from natural populations.* Science, 2013. **339**(6121): p. 814-815.

777 71. Bundschuh, M., J.P. Zubrod, and R. Schulz, *The functional and physiological status*  
778 *of Gammarus fossarum (Crustacea; Amphipoda) exposed to secondary treated*  
779 *wastewater.* Environmental Pollution, 2011. **159**(1): p. 244-249.

780 72. <http://scidavis.sourceforge.net> 2016.

781 73. Nichols, J.W., et al., *Bioaccumulation assessment using predictive approaches.*  
782 Integrated Environmental Assessment and Management, 2009. **5**(4): p. 577-597.

783 74. Meredith-Williams, M., et al., *Uptake and depuration of pharmaceuticals in*  
784 *aquatic invertebrates.* Environmental Pollution, 2012. **165**: p. 250-258.

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804 **FIGURE CAPTIONS**


805 **Figure 1.** Mortality, expressed as a percentage of dead individuals, during the exposure  
806 experiments. A. Exposure experiments without surfactants. B. Exposure experiments with  
807 surfactants.

808 **Figure 2.** Bioconcentration curves of oxazepam in *Gammarus fossarum* sp. (a) Exposure  
809 media with oxazepam at  $1 \mu\text{g L}^{-1}$ . (b). Exposure media with surfactants at  $25 \mu\text{g L}^{-1}$  and  
810 oxazepam at  $1 \mu\text{g L}^{-1}$ . Curves obtained with SciDavies software.

811 **Figure 3.** Bioconcentration curves of sulfamethoxazole in *Gammarus fossarum* sp. (a)  
812 Exposure media with sulfamethoxazole at  $1 \mu\text{g L}^{-1}$ . (b) Exposure media with surfactants at  $\mu\text{g}$   
813  $\text{L}^{-1}$  and sulfamethoxazole at  $1 \mu\text{g L}^{-1}$ . For comparative purposes, both graphs have been  
814 depicted with the same scale on Y axis. Curves obtained with SciDavies software.

815 **Figure 4.** Depuration of oxazepam accumulated in *Gammarus fossarum* (without  
816 surfactants) over  $< 72$  h.

817 a.




818

819

820

821 b.




822

823  
824

**Figure 1.** Mortality, expressed as percentage of dead individuals, during the exposure experiments. A. Exposure experiments without surfactants. B. Exposure experiments with surfactants.

825 a)



826

827


828

829

830

831

832 b)



833

834

835 **Figure 2.** Bioconcentration curves of oxazepam in *Gammarus fossarum* sp. (a) Exposure media with oxazepam at 1  $\mu\text{g L}^{-1}$ . (b). Exposure media with surfactants at  
836 25  $\mu\text{g L}^{-1}$  and oxazepam at 1  $\mu\text{g L}^{-1}$ . Curves obtained with SciDavies software.


837

838

839

840

841 a.



842

843


844

845

846

847 b.

848




849

850

851 **Figure 3.** Bioconcentration curves of sulfamethoxazole in *Gammarus fossarum* sp. (a) Exposure media with sulfamethoxazole at 1  $\mu\text{g L}^{-1}$ . (b)  
852 Exposure media with surfactants at  $\mu\text{g L}^{-1}$  and sulfamethoxazole at 1  $\mu\text{g L}^{-1}$ . For comparative purposes, both graphs have been depicted with the  
853 same scale on Y axis. Curves obtained with SciDavies software.



854



855

856 **Figure 4.** Elimination of oxazepam accumulated in *Gammarus fossarum* (without surfactants) over < 72 h.

857 **Table 1.** Experimental (\*) and predicted physico-chemical properties of the studied pharmaceuticals.

	<b>MOLECULAR STRUCTURE</b>	<b>ELEMENTAL COMPOSITION</b>	<b>CAS NUMBER</b>	<b>MW (average)</b>	<b>SOLUBILITY (mg/L)</b>	<b>Log P</b>
<b>SULFAMETHOXAZOLE</b>		$C_{10}H_{11}N_3O_3S$	723-46-6	253.278	610* 459	0.89* 0.79
<b>OXAZEPAM</b>		$C_{15}H_{11}ClN_2O_2$	604-75-1	286.713	179* 88.1	2.24* 2.01-2.92

858

Source: [www.drugbank.ca](http://www.drugbank.ca) (07/2016)

859 **Table 2.** Surfactant levels determined in wastewater effluent from La Feysine wastewater treatment plant. LOQs are given in Bergé et al. [39].

SURFACTANT	Day 1	Day 2	Day 3	Day 4
Benzotriazole	4.80	4.29	3.70	3.03
Comperlan 100	< loq	< loq	< loq	< loq
Cetyl Betain	0.41	< loq	< loq	< loq
Triton X100	3.03	19.62	2.27	3.21
Stepanquat GA 90	< loq	< loq	< loq	< loq
BDDAC	5.24	0.53	0.96	0.37
BDTAC	<b>7.20</b>	0.13	0.55	< loq
Lauryl pyridinium	1.52	< loq	< loq	< loq
Incromine SD	< loq	< loq	< loq	< loq
Sodium 2-ethylhexyl sulfate	< loq	< loq	< loq	< loq
SDS	< loq	< loq	< loq	< loq
LAS C10	3.69	23.15	21.25	28.20
LAS C11	< loq	<b>33.75</b>	2.51	19.55
LAS C12	< loq	<b>34.20</b>	< loq	7.87
LAS C13	< loq	24.55	< loq	< loq
Texapon N 701 S	< loq	< loq	< loq	< loq

860

861 **Table 3.** Measured concentration of the studied pharmaceuticals in the experimental tests (n=3)

		Day 3			Day 13		
		C (ng L <sup>-1</sup> )	SDV	RSD(%)	C (ng L <sup>-1</sup> )	SDV	RSD(%)
SULFAMETHOXAZOLE	<i>No-surfactants</i>	752.5	107.6	14.3	851.5	44.5	5.2
	<i>Surfactants</i>	755.5	91.1	12.1	830.3	39.6	4.8
OXAZEPAM	<i>No-surfactants</i>	1016.7	29.4	2.9	1009.7	22.1	2.2
	<i>Surfactants</i>	955.2	41.9	4.4	997.7	23.5	2.3

**Table 4.** Uptake and depuration constants ( $K_{in}$  and  $K_{out}$ , respectively) and bioconcentration factor (BCF) estimated by SciDAVIs Software

	$K_{in}$	$K_{out}$	BCF ( L/Kg)
<b>Oxazepam no surfactants</b>	61.5 ± 12.3	0.68 ± 0.15	<b>90.4</b>
<b>Oxazepam surfactants</b>	44.5 ± 6.9	0.62 ± 0.11	<b>71.8</b>
<b>Sulfamethoxazole no surfactants</b>	13.6 ± 5.7	0.26 ± 0.15	<b>52.3</b>
<b>Sulfamethoxazole surfactants</b>	11.8 ± 7.4	0.97 ± 0.67	<b>12.2</b>

## SUPPLEMENTARY INFORMATION

### 1. HPLC-MS/MS analysis of surfactants in for effluent wastewater (based on Bergé et al. *J Chrom A* 1450 (2016), 64-75

#### SPE EXTRACTION

Briefly, SPE extraction was carried out using cartridges Cunax2 (3 cc, 200 mg). They were conditioned with 8 mL of MeOH, 4 mL of Milli-Q water and 4 mL of phosphate buffer (0.1 M at pH = 6). A volume of 200 mL was loaded onto the cartridges, and after that they were washed with 5 mL of phosphate buffer and dried under vacuum for 10 min. Elution was performed separately, first with 2 x 5 mL of ACN and then with 2 x 5 mL of ACN with 5% of NH<sub>4</sub>OH. Both fractions were collected separately, evaporated to dryness under a gentle N<sub>2</sub> stream (45°C) and reconstituted to 1 mL each, with ACN/H<sub>2</sub>O (65/35; v/v). Finally, both extracts were put together in one vial.

#### HPLC-MS/MS ANALYSIS

HPLC-MS/MS analyses were performed with an Agilent 1200 LC system (Massy, France), equipped with a quaternary pump, followed by an API-3200 QTRAP from ABSciex (Les Ulis, France). ABSciex software Analyst 1.6.1 version was used for data collection and instrument control. Analyses in both positive and negative ionization modes were carried out using an Acclaim Surfactant Plus column (3 µm, 150×3 mm, 3.0 µm) preceded by an Acclaim surfactant Plus guard-column, (5 µm, 3×10 mm), both from Thermo Fischer (Illkirch, France). The mobile phases were 0.1 M ammonium acetate in Milli-Q water (pH=5.0)(A), Milli-Q water (B) and ACN (C). The gradient is shown in Table S1.

**Table S1.** Elution gradient used for the surfactants analysis.

<b>t (min)</b>	<b>%A</b>	<b>%B</b>
<b>0</b>	70%	30%
<b>1</b>	70%	30%
<b>8</b>	15%	85%
<b>20</b>	15%	85%

The analyses were performed in multiple reaction monitoring (MRM) mode, using the two most abundant transitions, for quantification and confirmation respectively. MRM transitions for the surfactants are given in Table S2.

**Table S2.** MS/MS conditions for the surfactants studied ([Bergé et al. J Chrom A 1450 \(2016\). 64-75](#))

SURFACTANT	Ionization mode	Precursor ion [M+H] <sup>+</sup>	MRM Transitions	RT (m)	DP (V)	EP (V)	CE (V)	CXP (V)
Benzotriazole	ESI +	120.1	65	1.7	46	10	23	4
			92		46	10	23	4
BDDAC	ESI +	304.2	91.1	2.6	51	12	45	4
			212.3		51	12	27	4
BDTAC	ESI +	332.4	91	3.7	46	11	49	4
			240.3		46	11	29	4
Stepanquat GA 90	ESI +	402.4	283.3	4.3	56	10.5	31	4
			57.1		56	10.5	65	4
Lauryl pyridinium	ESI +	248.3	80.1	1.7	66	10.5	33	4
			57.1		66	10.5	37	4
Incromine SD	ESI +	369.4	324.4	5.0	46	12	31	4
			57.1		46	12	57	4
Sodium 2-ethylhexyl sulfate	ESI -	209.2	96.8	7.4	-55	-3	-32	0
			79.8		-55	-3	-60	0
SDS	ESI -	265.1	96.9	9.2	-65	-3	-36	-2
			79.8		-65	-3	-82	0
LAS C10	ESI -	297.1	119	9.5	-75	-10	-62	0
			184		-75	-10	-38	0
LAS C11	ESI -	311.1	118.9	9.9	-80	-12	-68	-2
			182.8		-80	-12	-48	0
LAS C12	ESI -	325.1	118.8	9.9	-85	-12	-70	0
			182.8		-85	-12	-48	0
LAS C13	ESI -	339.2	118.9	10.3	-95	-12	-72	0
			182.8		-95	-12	-50	0
Texapon N 701 S	ESI -	293.1	79.8	10.7	-55	-2.5	-100	0
			96.2		-55	-2.5	-40	0
Comperlan 100	ESI +	244.2	62.1	5.6	31	10	33	4
			57.1		31	10	35	4
Triton X100	ESI +	532.4	89.1	5.4	46	10	41	4
			133.1		46	10	33	4
		576.4	89	5.4	51	10	47	4

			133.1		51	10	33	4
		620.5	89	5.3	61	9.5	51	4
			133.2		61	9.5	37	4
		664.5	89.2	5.2	61	12	51	4
			133.1		61	12	37	4
		708.5	89.1	5.1	66	10	51	4
			133.1		66	10	41	4
<b>Cetyl Betain</b>	ESI +	328.3	104.1	6.6	66	12	31	4
			85.1		66	12	35	4

**Table S3.** MS/MS optimization setting for the two pharmaceuticals used. SRM: selected reaction monitoring; DP: declustering potential; CE: collision energy; CXP: collision cell exit potential.

	Precursor ion [M+H] <sup>+</sup>	SRM transitions	DP(V)	CE(V)	CXP
<b>SULFAMETHOXAZOLE</b>	254	156	81	21	12
		92	81	35	12
<b>OXAZEPAM</b>	287	241.1	106	29	12
		269	106	23	16

### Nano-LC-MS/MS conditions

Both oxazepam and sulfamethoxazole were separated using (A) water with 0.1% of acetic acid and (B) MeOH:ACN:H<sub>2</sub>O(45:45:10) with 0.1% of acetic acid.

**Table S4.** Elution gradient used for oxazepam and sulfamethoxazole analysis in biota.

t (min)	%A	%B
<b>0</b>	90%	10%
<b>1.5</b>	90%	10%
<b>7</b>	0%	100%
<b>15</b>	0%	100%
<b>15.5</b>	90%	10%
<b>20</b>	90%	10%

**Table S5.** Environmental concentrations found in the literature for sulfamethoxazole and oxazepam.

	<b>WWTP effluent</b>	<b>Surface water</b>	<b>References</b>
<b>Sulfamethoxazole</b>	222	10-79	Gros et al, J Chrom A, 2012
	50-650	0,2-35,6	Garcia-Galan et al. Environ Int 2011
	10,8-284	-	Garcia-Galan et al. Sci Total Environ 2012
	55,1-532	-	Garcia-Galan et al. Anal Bioanal Chem 2012
	36,5-80	-	Papageorgiou et al. Sci Total Environ 2016
	10	-	Collado et al. Environ Pol, 2014
	41-8714*	-	Santos et al. Sci Total Environ 2013
	19-198	-	Gros et al. JCA, 2013
142-280**	-	Loos et al. Water Res 2013	
<b>Oxazepam</b>	1190-1700	28-53	Berlitz-Barbier et al, (submitted)
	162**	-	Loos et al. Water Res 2013
	80-160**	30-40**	Hass et al. Water Res 2012
	28-133	11-31	Kosjek et al. Water Res 2012

\*: hospital effluents; \*\*: average values


**Table S6.** Measured parameters during the experiment.

	Control solvents	Control surfactants	Oxazepam	Oxazepam +surfactants	Sulfamethoxazole	Sulfamethoxazole +surfactants
<b>pH</b>	7.73(0.34)	7.7(0.26)	7.9	7.9(0.2)	7.9(0.1)	7.8
<b>Temperature (°C)</b>	14.82(0.54)	14.7(1.7)	14.6(0.4)	14.6(1.8)	14.7(0.8)	15.3
<b>Conductivity (µS/cm)</b>	409.6(0.4)	408.9(0.2)	408.5(0.2)	408.9(0.1)	302.1(0.2)	434
<b>Dissolved O<sub>2</sub> (mg/L)</b>	5.1(7.6)	4.4(3.7)	6.6(2.5)	7(1.5)	6.9(1.3)	5.7

\*. Measurements were performed in the morning, right before changing the solutions.

**Table S7.** Inter individual variability (n=5) calculated for SMX and OXA analyses each day of sampling

Time of exposure (days)	OXAZEPAM	OXAZEPAM (with surfactants)	SMX	SMX (with surfactants)
<b>1</b>	36.40	36.64	19.00	42.40
<b>2</b>	17.76	12.52	22.60	20.60
<b>3</b>	10.30	13.80	36.40	31.80
<b>4</b>	15.10	15.05	15.00	36.60



1

2 **Figure S1.** Feeding tests in the controls, expressed in leaf surface area

3

4

5

6